ALLOGENE THERAPEUTICS INC's ticker is ALLO and the CUSIP is 019770106. A total of 185 filers reported holding ALLOGENE THERAPEUTICS INC in Q2 2021. The put-call ratio across all filers is 1.00 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $84,490 | -84.9% | 26,653 | -76.4% | 0.00% | – |
| Q2 2023 | $561,128 | +88.1% | 112,903 | +86.9% | 0.00% | – |
| Q1 2023 | $298,381 | +370.0% | 60,401 | +498.4% | 0.00% | – |
| Q4 2022 | $63,491 | -96.4% | 10,094 | -93.9% | 0.00% | -100.0% |
| Q3 2022 | $1,782,000 | +85.4% | 165,007 | +95.7% | 0.00% | – |
| Q2 2022 | $961,000 | +76.0% | 84,301 | +40.8% | 0.00% | – |
| Q1 2022 | $546,000 | -72.8% | 59,865 | -55.4% | 0.00% | – |
| Q4 2021 | $2,004,000 | +133.6% | 134,313 | +302.7% | 0.00% | – |
| Q3 2021 | $858,000 | +86.9% | 33,354 | +89.5% | 0.00% | – |
| Q2 2021 | $459,000 | +9.3% | 17,600 | +48.0% | 0.00% | – |
| Q1 2021 | $420,000 | -44.2% | 11,895 | -60.2% | 0.00% | – |
| Q4 2020 | $753,000 | -33.4% | 29,858 | -0.4% | 0.00% | -100.0% |
| Q3 2020 | $1,130,000 | -16.0% | 29,977 | -4.5% | 0.00% | 0.0% |
| Q2 2020 | $1,345,000 | +80.8% | 31,405 | +15.1% | 0.00% | 0.0% |
| Q3 2019 | $744,000 | – | 27,295 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| VV Manager LLC | 1,798,163 | $76,997,000 | 67.53% |
| Wildcat Capital Management, LLC | 1,515,524 | $64,895,000 | 22.42% |
| TPG Group Holdings (SBS) Advisors, Inc. | 19,716,306 | $844,252,000 | 14.91% |
| REGENTS OF THE UNIVERSITY OF CALIFORNIA | 1,279,281 | $54,779,000 | 7.69% |
| Coastal Bridge Advisors, LLC | 463,117 | $19,831,000 | 6.33% |
| DSAM Partners (London) Ltd | 235,098 | $10,067,000 | 2.63% |
| Casdin Capital, LLC | 625,000 | $26,763,000 | 1.58% |
| Alpine Global Management, LLC | 150,000 | $6,423,000 | 1.13% |
| Perceptive Advisors | 1,543,790 | $66,105,000 | 1.07% |
| Avoro Capital Advisors LLC | 1,128,594 | $48,326,000 | 0.96% |